NICE
UK's NICE Recommends Selpercatinib for RET-Altered Thyroid Cancers Through Cancer Drugs Fund
While data mature, NICE recommends that Eli Lilly's drug be available to certain RET fusion-positive thyroid cancer or RET-mutant medullary thyroid cancer patients.
UK's NICE Recommends Roche's Tecentriq for First-Line PD-L1-Positive Bladder Cancer
The committee recommends the agent be available to patients whose cancers express PD-L1 in at least 5 percent of cells and for whom platinum chemo isn't an option.
UK's NICE Supports Keytruda With Chemo for PD-L1 Positive Esophageal Cancer Patients
The agency said the life-extending treatment would be cost-effective for NHS to provide as a first-line option for certain esophageal and gastro-esophageal junction cancers.
UK's MHRA Grants Early Access to Amgen's Lumakras for KRAS-Mutant Lung Cancer
The drug will be available to patients in England through an expedited conditional approval, while NICE completes its appraisal for full approval.
NICE Recommends Incyte's Pemazyre for FGFR2-Positive Bile Duct Cancer
The drug was approved in the UK for previously treated patients with locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement.